🇺🇸 FDA
Pipeline program

In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

APHP 211033

Phase 1 other active

Quick answer

In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ) for Cardiology and vascular disease is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Cardiology and vascular disease
Phase
Phase 1
Modality
other
Status
active

Clinical trials